Reference
Wu Y, et al. Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer. OncoTargets and Therapy 15: 973-979, Jan 2022. Available from: URL: https://www.dovepress.com/getfile.php?fileID=83844
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1962, 46 (2023). https://doi.org/10.1007/s40278-023-41716-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-41716-4